For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Yuhan Corporation

Calculating rank

USPTO Granted Patents = 100

% Expired Patents = 28.0

CIPO Patents = 2

EPO Patents = 36

Trademarks = 6

Forward Citations = 218

Loading Chart...

Loading Chart...

334 inventors (with patents filed for the assignee):

Hyun Ju (15 out of 15 patents)

Moo Young Song (14 out of 14 patents)

Ja-Heouk Khoo (13 out of 13 patents)

4. Tae Dong Han (13 out of 13 patents)

5. Jong Wook Lee (13 out of 14 patents)

6. Dong-Hoon Kim (12 out of 44 patents)

7. Hyun Ho Choi (12 out of 71 patents)

8. Su Bin Choi (11 out of 11 patents)

9. Hee Jae Tak (10 out of 10 patents)

10. Sol Park (10 out of 13 patents)

11. Na Ry Ha (10 out of 10 patents)

12. Mi Kyeong Ju (10 out of 10 patents)

13. Young-Ae Yoon (10 out of 10 patents)

14. Eun Kyung Kim (10 out of 12 patents)

15. Jong Gyun Kim (9 out of 21 patents)

Core Competencies:

EGFR Tyrosine Kinase

Aminopyrimidine

Bispecific Antibody

Pharmaceutical Composition

Mutant Kinase

Triazolone Derivatives

Humanized Antibody

Quinazoline Derivative

Fused Ring Compound

Protein Kinase Inhibitors

Dual Function Proteins

Tumor Necrosis Factor

100 patents: Sort by Forward Citations

1. 12780931 - METHODS FOR PURIFYING AN ANTI-4-1BB/ANTI-HER2 BISPECIFIC ANTIBODY (2026-11-03),

2. 12780918 - Antigen Binding Proteins that Bind PD-L1 (2026-11-03),

3. 12774311 - USE OF LONG-ACTING FGF21 FUSION PROTEINS IN TREATING FGF21-ASSOCIATED DISORDERS (2026-10-27),

4. 12686665 - Bicyclic fused ring derivative or salt thereof and pharmaceutical composition comprising same (2026-07-21),

5. 12673944 - Compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same (2026-07-07),

6. 12599606 - THERAPIES WITH 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS (2026-04-14),

7. 12522602 - Derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2026-01-13),

8. 12428401 - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same (2025-09-30),

9. RE50528 - Compounds and compositions for modulating EGFR mutant kinase activities (2025-08-12),

10. 12338237 - Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2025-06-24),

11. 12318390 - Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt (2025-06-03),

12. 12258328 - 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

13. 12258327 - 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

14. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

15. 12227478 - Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same (2025-02-18),

Company Overview

Yuhan Corporation, headquartered in Seoul, South Korea, is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of innovative therapies. The company focuses on EGFR inhibitors, leveraging advanced technologies such as EGFR tyrosine kinase and bispecific antibodies to address various oncological conditions. Yuhan's research encompasses a range of core topics, including aminopyrimidine and triazolone derivatives, positioning it as a leader in targeted cancer treatments and contributing significantly to the global healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

100 Patents

#75 in Seoul

#188 in South Korea

#7,798 in the World

Seoul, South Korea

Yuhan Corporation

Forward Citations = 218

334 inventors:

Hyun Ju (15 out of 15 patents)

Moo Young Song (14 out of 14 patents)

Ja-Heouk Khoo (13 out of 13 patents)

4. Tae Dong Han (13 out of 13 patents)

5. Jong Wook Lee (13 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Yuhan Corporation. Retrieved from https://idiyas.com/company/yuhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…